Navigation Links
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Date:10/18/2007

ed as high risk and are candidates for stem cell transplantation. Optimization of treatment and reduction of relapse of patients with MRD-positive ALL represent an absolute medical need especially in patients for whom stem cell transplantation is not an option. Although CD19 is widely expressed in ALL, no antibody against this tumor associated antigen target has been developed thus far. The current clinical trial is set up to address the question of treating MRD positive ALL with a novel anti-CD19 antibody derivative," said Professor Hoelzer, Chairman of the GMALL study group.

Early observations of MT103 clinical activity were recently reported from an ongoing phase 1 clinical trial evaluating MT103 as single-agent therapy in a population of heavily pre-treated patients with NHL. These observations included complete and partial responses confirmed by independent review. In addition, MT103 not only eliminated tumor target cells in peripheral blood but also cleared lymphoma cells from heavily infiltrated bone marrow. These data were presented at the 48th Annual Meeting of the American Society for Hematology in December 2006.

"The upcoming phase 2 clinical trial in ALL is an important step to establish activity of MT103 in aggressive B cell leukemias and lymphomas," said Carsten Reinhardt, Micromet's Senior Vice President and Chief Medical Officer. "Investigating the effect of MT103 on minimal residual disease may open a highly promising new treatment concept in these diseases, that is, consolidation therapy with a BiTE antibody (MT103) after initial treatment with a chemotherapeutic regimen."

About BiTE(R) Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... The 2015 New York ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
(Date:8/31/2015)... ... ... The Bay Pines VA Healthcare System (VAHCS) remains focused on ... doctors and nurses and expanding existing facilities and services. Spine surgery will soon ... Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine surgery ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Surgery Program at Monmouth, was one of the first doctors in the area ... of this new approach have been impressive: faster recovery, decreased immediate and long-term ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Dr. Stewart ... may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination can diagnose ... common cause of visual impairment among children, affecting approximately 2 to 3 out of ...
(Date:8/31/2015)... ... August 31, 2015 , ... The dental implant and prosthetic market in the ... Implant Dentistry. (See Press Room ) More than 30 million Americans are missing ... the increasing demand for dental implants, the National Association of Dental Laboratories (NADL) created ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4
... Taiwan researchers said Thursday they have successfully tested 10 ... while prolonging patients' survival time with limited side ... led by Dr. Wong Chi-huey, president of Taiwan's highest ... in the structure and function of sugars. ...
... all financial aid to Amnesty International and called on ... accusing it of promoting abortion. "No more Catholic ... said a statement from the Vatican's Pontifical Council for ... Renato Martino, said the "suspension of all financing of ...
... concept catching up fast in the West. ,With the ... phones with hundreds of names and numbers stored in its ... these numbers belong to the near and dear. ,In ... had a heart attack and the physicians attending on the injured ...
... for Allergy & Immunology (LIAI) made an important finding, ... for treating autoimmune and inflammatory diseases such as ... studies, conducted in laboratory mice, demonstrated the role of ... broken down in the body, in regulating inflammation. ...
... Melbourne's Yarra River, posing serious threat to wildlife in the ... with the water until the slick - from the Chandler ... ,The Environment Protection Agency (EPA) is investigating the source ... but was not discovered until Tuesday by a kayaker using ...
... University of Illinois at Chicago and Cornell University are ... patients who suffer from Neurodegenerative diseases or stroke . ... events take place that lead to the death of ... called histone deacetylases can modulate gene expression, and in ...
Cached Medicine News:Health News:Taiwan Researchers Claim Cancer Therapy Alternative 2Health News:Catholics Should Halt Amnesty Support Over Abortion Issue: Vatican 2Health News:Look Out for ICE in Emergency Situations 2Health News:New Therapeutic Approach for Autoimmune and Inflammatory Diseases 2Health News:Australia Battles Oil Slick on Yarra River 2Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, ... EURONEXT: SAN) and the life sciences team at Google ... and outcomes for people with type 1 and type ... and devices with Google,s expertise in analytics, miniaturized electronics ... how to improve diabetes care by developing new tools ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: